Pesquisar
Rallybio Corp
RLYBAdicionar à lista de desejos
15.815USD
-0.125-0.78%
Fechamento 07/02, 13:00（ET）Cotações atrasadas em 15 min
82.90MValor de mercado
PerdaP/L TTM
Mais detalhes de Rallybio Corp Empresa
Rallybio Corporation is a clinical-stage biotechnology company engaged in developing and commercializing life-transforming therapies for patients with severe and rare diseases. It has a pipeline of product candidates aimed at addressing diseases with unmet medical need in the areas of complement dysregulation and hematology. The Company’s lead program, RLYB116, is a differentiated C5 inhibitor with the potential to treat diseases of complement dysregulation, with an initial focus on immune platelet transfusion refractoriness (PTR) and refractory antiphospholipid syndrome (APS). RLYB116 is a novel, once-weekly, small volume, subcutaneously injected C5 inhibitor designed to meet patient demand for a convenient, self-administered at-home solution. Its pipeline also includes RLYB332, a preclinical long-acting matriptase-2 antibody for the treatment of diseases of iron overload. Its RLYB114 is a pegylated C5 inhibitor in development for complement-mediated ophthalmic disorders.
Informações de Rallybio Corp
Código da empresaRLYB
Nome da EmpresaRallybio Corp
Data de listagemJul 29, 2021
CEOUden (Stephen)
Número de funcionários25
Tipo de títulosOrdinary Share
Fim do ano fiscalJul 29
Endereço234 Church Street
CidadeNEW HAVEN
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal06510
Telefone12038593820
Sitehttps://rallybio.com/
Código da empresaRLYB
Data de listagemJul 29, 2021
CEOUden (Stephen)
Executivos da empresa Rallybio Corp
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Stephen (Steve) Uden, M.D.
Dr. Stephen (Steve) Uden, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
92.54K
+0.67%
Mr. Jonathan I. (Jon) Lieber
Mr. Jonathan I. (Jon) Lieber
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
4.12K
-0.02%
Ms. Paula Soteropoulos
Ms. Paula Soteropoulos
Independent Director
Independent Director
2.98K
-0.10%
Dr. Steven W. Ryder, M.D.
Dr. Steven W. Ryder, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Ms. Helen M. Boudreau
Ms. Helen M. Boudreau
Independent Director
Independent Director
--
--
Dr. Robert (Rob) Hopfner, Ph.D.
Dr. Robert (Rob) Hopfner, Ph.D.
Independent Director
Independent Director
--
--
Mr. Ronald M. (Ron) Hunt
Mr. Ronald M. (Ron) Hunt
Independent Director
Independent Director
--
--
Dr. Lucian Iancovici, M.D.
Dr. Lucian Iancovici, M.D.
Independent Director
Independent Director
--
--
Ms. Christine A. Nash
Ms. Christine A. Nash
Independent Director
Independent Director
--
--
Dr. Hui Liu, Ph.D.
Dr. Hui Liu, Ph.D.
Independent Director
Independent Director
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Stephen (Steve) Uden, M.D.
Dr. Stephen (Steve) Uden, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
92.54K
+0.67%
Mr. Jonathan I. (Jon) Lieber
Mr. Jonathan I. (Jon) Lieber
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
4.12K
-0.02%
Ms. Paula Soteropoulos
Ms. Paula Soteropoulos
Independent Director
Independent Director
2.98K
-0.10%
Dr. Steven W. Ryder, M.D.
Dr. Steven W. Ryder, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Ms. Helen M. Boudreau
Ms. Helen M. Boudreau
Independent Director
Independent Director
--
--
Dr. Robert (Rob) Hopfner, Ph.D.
Dr. Robert (Rob) Hopfner, Ph.D.
Independent Director
Independent Director
--
--
Perguntas frequentes
Quem são os cinco principais acionistas de Rallybio Corp?
Os cinco principais acionistas de Rallybio Corp são: Dr. Stephen (Steve) Uden, M.D.
Quantas instituições possuem ações da Rallybio Corp (RLYB)?
Em 2026Q1, 138 instituições possuíam ações da Rallybio Corp, com valor de mercado aproximado de 3.48M, representando 65.82% do total de ações. Em comparação com 2025Q4, a participação institucional aumentou em -412366.00.